Naseem Zojwalla sold $7.5M of OLMA
Chief Medical Officer at Olema Pharmaceuticals, Inc.. 269,509 shares at an average of $27.94, traded Dec 19, 2025, filed Dec 23, 2025.
Score components
- +15RoleOfficer
- +25Trade size$7.5M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.5%, 3m -49.7%, 6m -61.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001905871-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | MOption exercise Common Stock | +40,000 | $15.25 | $610k | 173,997 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock | -57,079 | $28.03 | $1.6M | 116,918 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock | -12,921 | $28.93 | $374k | 103,997 | Dec 23, 2025 |
| Dec 22, 2025 | MOption exercise Common Stock | +42,818 | $15.25 | $653k | 146,815 | Dec 23, 2025 |
| Dec 22, 2025 | MOption exercise Common Stock | +7,182 | $7.02 | $50k | 153,997 | Dec 23, 2025 |
| Dec 22, 2025 | SOpen-market sale Common Stock | -100,000 | $28.04 | $2.8M | 53,997 | Dec 23, 2025 |
| Dec 23, 2025 | MOption exercise Common Stock | +50,000 | $7.02 | $351k | 103,997 | Dec 23, 2025 |
| Dec 23, 2025 | SOpen-market sale Common Stock | -99,509 | $27.66 | $2.8M | 4,488 | Dec 23, 2025 |
| Dec 19, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -40,000 | $0.00 | $0 | 155,000 | Dec 23, 2025 |
| Dec 22, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -42,818 | $0.00 | $0 | 112,182 | Dec 23, 2025 |
| Dec 22, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -7,182 | $0.00 | $0 | 206,818 | Dec 23, 2025 |
| Dec 23, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 156,818 | Dec 23, 2025 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $291k 25,000 shares | -3% | |
| 44Moderate | OLMAsell Olema Pharmaceuticals, Inc. | Shawnte Mitchell CHIEF LEGAL OFFICER | $952k 40,000 shares | -267% | |
| 43Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $269k 10,000 shares | -1% | |
| 40Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $102k 3,489 shares | -0% | |
| 65Notable | Olema Pharmaceuticals, Inc. | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | $3.0M 103,822 shares | -43% | |
| 60Notable | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $3.1M 110,000 shares | -71% | |
| 39Weak | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $82k 2,881 shares | -0% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Ian T Clark director | $7.9M 264,800 shares | -100% | |
| 55Moderate | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $1.6M 51,000 shares | -8% | |
| 27Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $205k 25,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.